1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This program’s application page is no longer available.
Historical funding: Not specified
Prior eligibility: Public and state controlled institutions of higher education, private institutions of higher education, and various non-profit and for-profit organizations are eligible.
Research to Address Vaccine Hesitancy and Uptake (R01 Clinical Trial Optional) is sponsored by National Institutes of Health (NIH). This program aims to address vaccine hesitancy and increase vaccine uptake through research. While not exclusively focused on patient engagement or community voice, successful interventions often involve understanding and incorporating community perspectives.
PAR-27-003 opens the NIGMS-style RM1 to 13 NIH institutes through September 2029: 3 to 6 PIs, up to $1.5M in direct costs a year but most awards $500K to $900K, at least 2.4 months of effort per PI, and a 20-page strategy with a mandatory Team Integration Plan. The NIGMS predecessor made 4 new awards in three years.
Read articleThe October 6, 2026 Director's Awards cohort is NIH's most expensive in four years at about $4.1 million per award. New Innovator rebounded from 29 to 42 while Early Independence fell from 13 to 3 after the program skipped its FY2026 competition. Here is what the composition shift means for FY2027 and FY2028 applicants.
Read articleOn October 7, 2026, Biohub, DOE, NIH, Google DeepMind, Isomorphic Labs and Meta committed $1.8 billion to build AI-ready biological data. More than $500 million of it is DOE money flowing through the Genesis Mission, and NIH's share is data rather than dollars. There is no NOFO — here is where the applyable money actually sits.
Read article